- Home
- NNOX vs AGEN Comparison
NNOX vs AGEN Comparison
Compare NNOX & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NNOX | AGEN |
|---|---|---|
| Founded | 2011 | 1994 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Medical Electronics | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 155.6M | 126.2M |
| IPO Year | 2019 | 1999 |
Fundamental Metrics
Financial Performance| Metric | NNOX | AGEN |
|---|---|---|
| Price | $2.70 | $2.98 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | $7.00 | ★ $14.50 |
| AVG Volume (30 Days) | ★ 879.4K | 381.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.37 |
| Revenue | N/A | ★ $42,877,086.00 |
| Revenue This Year | $20.19 | $5.19 |
| Revenue Next Year | $137.69 | $68.25 |
| P/E Ratio | ★ N/A | $7.88 |
| Revenue Growth | N/A | ★ 89.95 |
| 52 Week Low | $2.11 | $1.38 |
| 52 Week High | $6.22 | $7.34 |
Technical Indicators
Market Signals| Indicator | NNOX | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | 55.86 | 43.35 |
| Support Level | $2.11 | $2.90 |
| Resistance Level | $3.13 | $3.15 |
| Average True Range (ATR) | 0.15 | 0.18 |
| MACD | 0.06 | 0.00 |
| Stochastic Oscillator | 90.94 | 15.79 |
Price Performance
Historical ComparisonAbout NNOX NANO-X IMAGING LTD
Nano X Imaging Ltd is engaged in the business of manufacturing medical imaging systems. It offers a Nanox System which is a combination of hardware and software. It develops a prototype of the Nanox.ARC, a medical imaging system incorporating its novel digital X-ray source; and Nanox.CLOUD, a companion cloud-based software that will allow for the delivery of medical screening as a service. It has three business segments: Nanox.ARC division, the radiology services division and the AI solutions division. Key revenue is generated from Radiology Services.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).